Saadh M, Jasim N, Ahmed M, Ballal S, Kumar A, Atteri S
Clin Exp Med. 2025; 25(1):66.
PMID: 39998742
PMC: 11861128.
DOI: 10.1007/s10238-025-01600-7.
Mzoughi S, Schwarz M, Wang X, Demircioglu D, Ulukaya G, Mohammed K
Nat Genet. 2025; 57(2):402-412.
PMID: 39930084
PMC: 11821538.
DOI: 10.1038/s41588-024-02058-1.
Martinez-Bernabe T, Pons D, Oliver J, Sastre-Serra J
Biomolecules. 2024; 14(11).
PMID: 39595536
PMC: 11591675.
DOI: 10.3390/biom14111359.
Wang H, Tang R, Jiang L, Jia Y
Front Pharmacol. 2024; 15:1494802.
PMID: 39555098
PMC: 11565213.
DOI: 10.3389/fphar.2024.1494802.
Eikanger M, Sane S, Schraufnagel K, Slunecka J, Potts R, Freeling J
Res Sq. 2024; .
PMID: 39502780
PMC: 11537347.
DOI: 10.21203/rs.3.rs-5199838/v1.
Snail Expression as a Prognostic Factor in Colorectal Adenocarcinoma.
Hutasoit G, Miskad U, Akil F, Cangara M, Dahlan H, Yamin A
Asian Pac J Cancer Prev. 2024; 25(9):3143-3149.
PMID: 39342593
PMC: 11700324.
DOI: 10.31557/APJCP.2024.25.9.3143.
Targeting SNAI1-Mediated Colorectal Cancer Chemoresistance and Stemness by Sphingosine Kinase 2 Inhibition.
Janakiraman H, Gao Z, Zhu Y, Dong J, Becker S, Janneh A
World J Oncol. 2024; 15(5):744-757.
PMID: 39328328
PMC: 11424120.
DOI: 10.14740/wjon1890.
Intricate relationship between cancer stemness, metastasis, and drug resistance.
Dakal T, Bhushan R, Xu C, Gadi B, Cameotra S, Yadav V
MedComm (2020). 2024; 5(10):e710.
PMID: 39309691
PMC: 11416093.
DOI: 10.1002/mco2.710.
The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance.
Zhong C, Wang G, Guo M, Zhu N, Chen X, Yan Y
Cancer Control. 2024; 31:10732748241274196.
PMID: 39215442
PMC: 11367616.
DOI: 10.1177/10732748241274196.
Prioritizing cervical cancer candidate genes using chaos game and fractal-based time series approach.
Mallikarjuna T, Thummadi N, Vindal V, Manimaran P
Theory Biosci. 2024; 143(3):183-193.
PMID: 38807013
DOI: 10.1007/s12064-024-00418-3.
Integration of single-cell sequencing and bulk RNA-seq to identify and develop a prognostic signature related to colorectal cancer stem cells.
Wu J, Li W, Su J, Zheng J, Liang Y, Lin J
Sci Rep. 2024; 14(1):12270.
PMID: 38806611
PMC: 11133358.
DOI: 10.1038/s41598-024-62913-3.
Signaling, cancer cell plasticity, and intratumor heterogeneity.
Cordani M, Dando I, Ambrosini G, Gonzalez-Menendez P
Cell Commun Signal. 2024; 22(1):255.
PMID: 38702718
PMC: 11067149.
DOI: 10.1186/s12964-024-01643-5.
The Impact of Cancer Stem Cells in Colorectal Cancer.
Radu P, Zurzu M, Tigora A, Paic V, Bratucu M, Garofil D
Int J Mol Sci. 2024; 25(8).
PMID: 38673727
PMC: 11050141.
DOI: 10.3390/ijms25084140.
The epigenetic landscape in intestinal stem cells and its deregulation in colorectal cancer.
Larue A, Atlasi Y
Stem Cells. 2024; 42(6):509-525.
PMID: 38597726
PMC: 11177158.
DOI: 10.1093/stmcls/sxae027.
Macrophage-enriched novel functional long noncoding RNAs LRRC75A-AS1 and GAPLINC regulate polarization and innate immune responses.
Valverde A, Naqvi R, Naqvi A
Inflamm Res. 2024; 73(5):771-792.
PMID: 38592458
DOI: 10.1007/s00011-024-01865-w.
Keystone pathobionts associated with colorectal cancer promote oncogenic reprograming.
Jones J, Shi Q, Nath R, Brito I
PLoS One. 2024; 19(2):e0297897.
PMID: 38363784
PMC: 10871517.
DOI: 10.1371/journal.pone.0297897.
PROX1 interaction with α-SMA-rich cancer-associated fibroblasts facilitates colorectal cancer progression and correlates with poor clinical outcomes and therapeutic resistance.
Lai S, Cheng Y, Kiu K, Yen M, Chen Y, Yadav V
Aging (Albany NY). 2024; 16(2):1620-1639.
PMID: 38244581
PMC: 10866434.
DOI: 10.18632/aging.205447.
c-Fos regulated by TMPO/ERK axis promotes 5-FU resistance via inducing NANOG transcription in colon cancer.
Gui Y, Qian X, Ding Y, Chen Q, Ye F, Ye Y
Cell Death Dis. 2024; 15(1):61.
PMID: 38233377
PMC: 10794174.
DOI: 10.1038/s41419-024-06451-w.
Circular RNA ZNF800 (hsa_circ_0082096) regulates cancer stem cell properties and tumor growth in colorectal cancer.
Rengganaten V, Huang C, Wang M, Chien Y, Tsai P, Lan Y
BMC Cancer. 2023; 23(1):1088.
PMID: 37950151
PMC: 10636831.
DOI: 10.1186/s12885-023-11571-1.
Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer.
Finnegan E, Ding W, Ude Z, Terer S, McGivern T, Blumel A
Cell Oncol (Dordr). 2023; 47(2):533-553.
PMID: 37934338
PMC: 11090832.
DOI: 10.1007/s13402-023-00882-x.